iving well with memory difficulties in Parkinsonism

Not Applicable

Completed

• Conditions: Parkinson's disease dementia and dementia with Lewy bodies; Mental and Behavioural Disorders; Dementia

• Registration Number: ISRCTN16584442
• Lead Sponsor: Betsi Cadwaladr University Health Board

Brief Summary

2016 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/27000036 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/27446628 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29314218 [added 15/03/2019]

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-13
• Study Completion: 2017-01-01
• Last Update Posted: 1 April 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Current inclusion criteria as of 22/06/2015:
1. Diagnosis of Parkinson's disease (PD) according to the UK PD Brain Bank Diagnostic Criteria and a diagnosis of PD dementia according to the Movement Disorder Society consensus criteria or
2. Diagnosis of Dementia with Lewy Bodies (DLB) according to the DLB Consortium consensus criteria.
3. Clinical diagnosis of mild to moderate dementia with an ACE-III score of =82
4. Participants will preferably have a carer or family member who is willing to participate but this is not an absolute requirement
5. Participants should be on stable medication for their Parkinsonism and cognition (including acetylcholinesterase inhibitors) for four weeks prior to commencement with no changes planned for the duration of the intervention. Any unplanned changes in medication during the intervention will be documented

Previous inclusion criteria:
1. Diagnosis of Parkinson's disease (PD) according to the UK PD Brain Bank Diagnostic Criteria and a diagnosis of PD dementia according to the Movement Disorder Society consensus criteria or;
2. Diagnosis of Dementia with Lewy Bodies (DLB) according to the DLB Consortium consensus criteria.
3. Clinical diagnosis of mild to moderate dementia with an ACE-III score of <80
4. Participants will preferably have a carer or family member who is willing to participate but this is not an absolute requirement
5. Participants should be on stable medication for their Parkinsonism and cognition (including acetylcholinesterase inhibitors) for four weeks prior to commencement with no changes planned for the duration of the intervention. Any unplanned changes in medication during the intervention will be documented

Exclusion Criteria

1. Lack of stability of Parkinson's disease (PD) medications, cognitive enhancers or psychotropic medication or substantial additions to medication in the four weeks before the trial or planned changes during the period of the trial
2. Other major psychiatric disorder not related to PD
3. Major depression
4. Other significant neurological disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Participants’ performance and satisfaction on goals, identified through the Bangor Goal-Setting Interview measure are rated at baseline and at follow-up visits (a 2 month post-intervention visit and a 6 month follow-up visit)